These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles. Cybulski C; Wokołorczyk D; Kluźniak W; Kashyap A; Gołąb A; Słojewski M; Sikorski A; Puszyński M; Soczawa M; Borkowski T; Borkowski A; Antczak A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Domagała P; Piotrowski K; Menkiszak J; Krzystolik K; Gronwald J; Jakubowska A; Górski B; Dębniak T; Masojć B; Huzarski T; Muir KR; Lophatananon A; Lubiński J; Narod SA; Br J Cancer; 2013 Jun; 108(12):2601-9. PubMed ID: 23722471 [TBL] [Abstract][Full Text] [Related]
3. Inherited NBN Mutations and Prostate Cancer Risk and Survival. Rusak B; Kluźniak W; Wokołorczykv D; Stempa K; Kashyap A; Gronwald J; Huzarski T; Dębniak T; Jakubowska A; Masojć B; Akbari MR; Narodv SA; Lubiński J; Cybulski C Cancer Res Treat; 2019 Jul; 51(3):1180-1187. PubMed ID: 30590007 [TBL] [Abstract][Full Text] [Related]
4. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population. Górski B Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018 [TBL] [Abstract][Full Text] [Related]
5. Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer? Lener MR; Scott RJ; Kluźniak W; Baszuk P; Cybulski C; Wiechowska-Kozłowska A; Huzarski T; Byrski T; Kładny J; Pietrzak S; Soluch A; Jakubowska A; Lubiński J Int J Cancer; 2016 Aug; 139(3):601-6. PubMed ID: 27038244 [TBL] [Abstract][Full Text] [Related]
6. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Sokolenko AP; Rozanov ME; Mitiushkina NV; Sherina NY; Iyevleva AG; Chekmariova EV; Buslov KG; Shilov ES; Togo AV; Bit-Sava EM; Voskresenskiy DA; Chagunava OL; Devilee P; Cornelisse C; Semiglazov VF; Imyanitov EN Fam Cancer; 2007; 6(3):281-6. PubMed ID: 17333477 [TBL] [Abstract][Full Text] [Related]
7. Breast cancer predisposing alleles in Poland. Górski B; Cybulski C; Huzarski T; Byrski T; Gronwald J; Jakubowska A; Stawicka M; Gozdecka-Grodecka S; Szwiec M; Urbański K; Mituś J; Marczyk E; Dziuba J; Wandzel P; Surdyka D; Haus O; Janiszewska H; Debniak T; Tołoczko-Grabarek A; Medrek K; Masojć B; Mierzejewski M; Kowalska E; Narod SA; Lubiński J Breast Cancer Res Treat; 2005 Jul; 92(1):19-24. PubMed ID: 15980987 [TBL] [Abstract][Full Text] [Related]
8. Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele. Suspitsin EN; Yanus GA; Sokolenko AP; Yatsuk OS; Zaitseva OA; Bessonov AA; Ivantsov AO; Heinstein VA; Klimashevskiy VF; Togo AV; Imyanitov EN Med Oncol; 2014 Feb; 31(2):828. PubMed ID: 24415413 [TBL] [Abstract][Full Text] [Related]
9. Epidemiologic, clinical, and molecular characteristics of hereditary prostate cancer in Latvia. Abele A; Vjaters E; Irmejs A; Trofimovičs G; Miklaševičs E; Gardovskis J Medicina (Kaunas); 2011; 47(10):579-85. PubMed ID: 22186123 [TBL] [Abstract][Full Text] [Related]
10. The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome. Lener MR; Kashyap A; Kluźniak W; Cybulski C; Soluch A; Pietrzak S; Huzarski T; Gronwald J; Lubiński J Cancer Res Treat; 2017 Apr; 49(2):430-436. PubMed ID: 27488870 [TBL] [Abstract][Full Text] [Related]
11. BRCA1 mutations and prostate cancer in Poland. Cybulski C; Górski B; Gronwald J; Huzarski T; Byrski T; Debniak T; Jakubowska A; Wokołorczyk D; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Romuald Z; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Posmyk M; Narod SA; Lubiński J Eur J Cancer Prev; 2008 Feb; 17(1):62-6. PubMed ID: 18090912 [TBL] [Abstract][Full Text] [Related]
12. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients. Suspitsin EN; Sherina NY; Ponomariova DN; Sokolenko AP; Iyevleva AG; Gorodnova TV; Zaitseva OA; Yatsuk OS; Togo AV; Tkachenko NN; Shiyanov GA; Lobeiko OS; Krylova NY; Matsko DE; Maximov SY; Urmancheyeva AF; Porhanova NV; Imyanitov EN Hered Cancer Clin Pract; 2009 Feb; 7(1):5. PubMed ID: 19338682 [TBL] [Abstract][Full Text] [Related]
13. A common nonsense mutation of the BLM gene and prostate cancer risk and survival. Antczak A; Kluźniak W; Wokołorczyk D; Kashyap A; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Masojć B; Górski B; Gromowski T; Nagorna A; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Borkowski T; Borkowski A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Domagała P; Stawicka M; Milecki P; Akbari MR; Narod SA; Lubiński J; Cybulski C; ; ; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała W; Chosia M; van de Wetering T; Serrano-Fernández P; Puszyński M; Soczawa M; Switała J; Archimowicz S; Kordowski M; Zyczkowski M; Borówka A; Bagińska J; Krajka K; Szwiec M; Haus O; Janiszewska H; Stembalska A; Sąsiadek MM Gene; 2013 Dec; 532(2):173-6. PubMed ID: 24096176 [TBL] [Abstract][Full Text] [Related]
14. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378 [TBL] [Abstract][Full Text] [Related]
15. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916 [TBL] [Abstract][Full Text] [Related]
16. Allelic modification of breast cancer risk in women with an NBN mutation. Rusak B; Kluźniak W; Wokołorczyk D; Stempa K; Kashyap A; Rudnicka H; Gronwald J; Huzarski T; Dębniak T; Jakubowska A; Szwiec M; Akbari MR; Narod SA; Lubiński J; Cybulski C; Breast Cancer Res Treat; 2019 Nov; 178(2):427-431. PubMed ID: 31410679 [TBL] [Abstract][Full Text] [Related]
17. NBS1 is a prostate cancer susceptibility gene. Cybulski C; Górski B; Debniak T; Gliniewicz B; Mierzejewski M; Masojć B; Jakubowska A; Matyjasik J; Złowocka E; Sikorski A; Narod SA; Lubiński J Cancer Res; 2004 Feb; 64(4):1215-9. PubMed ID: 14973119 [TBL] [Abstract][Full Text] [Related]
18. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic]. Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209 [TBL] [Abstract][Full Text] [Related]
19. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland. Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C; Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559 [TBL] [Abstract][Full Text] [Related]